Clinical and Molecular Predictors of Response and Survival in Patients with Urothelial Carcinoma Treated with Enfortumab Vedotin: A Systematic Review and Meta-analysis

Background and objective: Enfortumab vedotin (EV) is emerging as a standard of care for advanced urothelial carcinoma (UC), but identification of which patients might benefit the most or least remains an unmet need. Our aim was to identify clinical and molecular parameters associated with EV sensiti...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Mohammed Altenni, Péter Fehérvári, Jakub Hoferica, Péter Hegyi, Nándor Ács, Tamás Fazekas, Judit Vargha, Viktor Grünwald, Christopher Darr, Péter Riesz, Péter Nyirády, Tibor Szarvas
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Elsevier 2025-12-01
Цуврал:	European Urology Open Science
Нөхцлүүд:	Enfortumab vedotin NECTIN4 FGFR Immune checkpoint inhibitor Urothelial carcinoma Meta-analysis
Онлайн хандалт:	http://www.sciencedirect.com/science/article/pii/S2666168325014417
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!